mucosal melanoma (Cancer)
Information
- Disease name
- mucosal melanoma
- Disease ID
- DOID:0050929
- Description
- "A melanoma that has_material_basis_in melanocytes located_in mucosal membranes lining the respiratory, gastrointestinal and urogenital tract." [url:http\://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466987/?report=classic]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03698019 | Active, not recruiting | Phase 2 | A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma | February 15, 2019 | September 21, 2024 |
| NCT00937937 | Active, not recruiting | Phase 2 | Dinaciclib in Treating Patients With Stage IV Melanoma | July 1, 2009 | March 8, 2025 |
| NCT03241186 | Active, not recruiting | Phase 2 | Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma | September 12, 2017 | September 2023 |
| NCT03033576 | Active, not recruiting | Phase 2 | Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma | October 23, 2017 | December 12, 2024 |
| NCT03178123 | Active, not recruiting | Phase 2 | The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery | May 31, 2017 | April 30, 2025 |
| NCT02126579 | Completed | Phase 1/Phase 2 | Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists | May 1, 2014 | May 5, 2021 |
| NCT02129075 | Completed | Phase 2 | A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma | April 9, 2014 | May 18, 2018 |
| NCT02158520 | Completed | Phase 2 | Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | October 18, 2013 | October 30, 2019 |
| NCT02519322 | Completed | Phase 2 | Neoadjuvant and Adjuvant Checkpoint Blockade | February 2, 2016 | January 26, 2023 |
| NCT02858869 | Completed | Phase 1 | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | October 4, 2016 | October 28, 2023 |
| NCT04551352 | Completed | Phase 1 | A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | October 28, 2020 | July 28, 2022 |
| NCT00110019 | Completed | Phase 3 | Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | June 2005 | August 2012 |
| NCT00424515 | Completed | Phase 2 | Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma | July 2006 | July 2011 |
| NCT01961115 | Completed | Phase 2 | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | September 13, 2013 | May 18, 2017 |
| NCT01989572 | Completed | Phase 3 | Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery | February 23, 2000 | January 31, 2013 |
| NCT00085189 | Completed | Phase 2 | Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma | May 2004 | September 2007 |
| NCT06424626 | Not yet recruiting | Phase 1 | A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma | May 21, 2024 | December 31, 2027 |
| NCT05545969 | Not yet recruiting | Phase 2 | Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma | March 2024 | May 2036 |
| NCT05436990 | Not yet recruiting | Phase 2 | Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor | July 2022 | December 2025 |
| NCT05086692 | Recruiting | Phase 1/Phase 2 | A Beta-only IL-2 ImmunoTherapY Study | August 27, 2021 | December 30, 2026 |
| NCT03611868 | Recruiting | Phase 1/Phase 2 | A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | August 29, 2018 | March 30, 2025 |
| NCT04462965 | Recruiting | Phase 2 | Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study | May 30, 2020 | June 30, 2025 |
| NCT04830124 | Recruiting | Phase 2 | Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 | May 27, 2021 | September 2025 |
| NCT05009446 | Recruiting | Early Phase 1 | Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM | August 10, 2021 | August 10, 2025 |
| NCT05111574 | Recruiting | Phase 2 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | August 11, 2022 | December 19, 2024 |
| NCT05384496 | Recruiting | Phase 2 | Axitinib and Nivolumab for the Treatment of Mucosal Melanoma | May 17, 2022 | May 2026 |
| NCT05420324 | Recruiting | Phase 2 | A Study to Assess YH003 in Combination With Pebolizumab and Albumin Paclitaxel Injection in Subjects With Unresectable/Metastatic Mucosal Melanoma | June 13, 2022 | September 2025 |
| NCT05628883 | Recruiting | Phase 1 | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | November 22, 2022 | December 31, 2026 |
| NCT05655312 | Recruiting | Phase 1/Phase 2 | MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma | June 1, 2023 | June 30, 2027 |
| NCT06319196 | Recruiting | Phase 2 | Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma | May 1, 2024 | February 15, 2030 |
| NCT01166126 | Terminated | Phase 2 | Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV | October 2010 | June 2012 |
| NCT02978443 | Terminated | Phase 2 | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | July 26, 2017 | August 2, 2022 |
| NCT03986515 | Unknown status | Phase 2 | Apatinib Plus SHR1210 in Advanced Mucosal Melanoma | June 4, 2019 | May 31, 2022 |
| NCT04180995 | Unknown status | Phase 2 | Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma | August 6, 2019 | December 30, 2022 |
| NCT03138642 | Unknown status | Phase 2 | Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era | July 1, 2010 | May 30, 2020 |
| NCT04353050 | Unknown status | N/A | Atypical MOLes and Melanoma Early Detection Study (MoleMed) | April 1, 2020 | November 1, 2023 |
| NCT03602547 | Unknown status | Phase 2 | Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma. | July 31, 2018 | June 2020 |
| NCT03319693 | Unknown status | Molecular Characterization of Primary Mucosal Melanoma | August 28, 2017 | April 28, 2021 | |
| NCT04622566 | Unknown status | Phase 2 | Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma | December 30, 2020 | December 30, 2023 |
| NCT04472806 | Unknown status | Phase 2 | Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma | June 20, 2020 | June 20, 2023 |
| NCT05482074 | Withdrawn | Phase 2 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | October 4, 2022 | May 1, 2027 |
| NCT03220009 | Withdrawn | Phase 2 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | November 3, 2017 | July 1, 2021 |
- Disase is a (Disease Ontology)
- DOID:1909